Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Faster recovery after ERCP? new trial tests two reversal drugs

NCT ID NCT06136585

Symptom relief Sponsor: The Cleveland Clinic Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study compares sugammadex and neostigmine to reverse muscle paralysis caused by rocuronium during ERCP, a procedure to treat bile duct issues. About 80 adults will be randomly assigned to one of the two drugs. The goal is to see which drug helps patients recover faster and causes fewer side effects like nausea.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
sugammadex and neostigmine
What this could lead to
If sugammadex works better, patients could recover faster and feel less sick after ERCP procedures.
What could go wrong
This is a small, early-phase trial focused on recovery time, not a cure. Results may not apply to all patients or procedures.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

About 80 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jun 2024

Expected to finish

Dec 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * ≥18 years old * American Society of Anesthesiologist physical status 3-4 * Scheduled for outpatient endoscopic retrograde cholangiopancreatography Exclusion Criteria: * Difficult Airway * Neuromuscular Disorders (eg: ALS, Botulism, Myasthenia Gravis, Lambert-eaton syndrome) * End stage renal disease requiring dialysis * Pregnancy or breast-feeding * Allergy to Fentanyl * Allergy to Neuromuscular blocking drugs (eg: rocuronium) * Allergy to Neuromuscular reversal drugs (eg: sugammadex or neostigmine) * Allergy to glycopyrrolate

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Neuromuscular blocks are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Neuromuscular blocks

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Cleveland Clinic Fairview Hospital

    RECRUITING

    Cleveland, Ohio, 44111, United States